irinotecan has been researched along with Acneiform Eruptions in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fokoue-Nkoutche, A; Hu, J; Luo, H; Singh, N; Yang, L; Zhang, P | 1 |
| Guo, GF; Jiang, WQ; Qiu, HJ; Wang, F; Xia, LP; Xu, RH; Zhang, B; Zhou, FF | 1 |
| Barbuzza, O; Guarneri, C; Pollicino, A; Vaccaro, M | 1 |
3 other study(ies) available for irinotecan and Acneiform Eruptions
| Article | Year |
|---|---|
Molecular Docking for Prediction and Interpretation of Adverse Drug Reactions.
Topics: Acneiform Eruptions; Algorithms; Binding Sites; Drug-Related Side Effects and Adverse Reactions; Fluticasone; Humans; Irinotecan; Libido; Machine Learning; Molecular Docking Simulation; Mometasone Furoate; Protein Binding; Protein Conformation; ROC Curve; Striae Distensae | 2018 |
[Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Topics: Acneiform Eruptions; Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Diarrhea; Disease-Free Survival; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; ras Proteins; Rectal Neoplasms; Remission Induction; Survival Rate | 2010 |
Acneiform eruption following molecular targeted chemotherapy.
Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Gene Targeting; Humans; Irinotecan; Male; Middle Aged | 2011 |